相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myelodysplasies (GFM)
Thomas Cluzeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia
Mohamed L. Sorror et al.
BLOOD (2021)
Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study
Richard F. Schlenk et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei et al.
BLOOD (2020)
Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).
Tapan M. Kadia et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
Heiko Becker et al.
ANNALS OF HEMATOLOGY (2020)
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
Christoph Roellig et al.
BLOOD (2020)
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy
Chong Chyn Chua et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy
Chetasi Talati et al.
LEUKEMIA RESEARCH (2020)
The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia A meta-analysis of randomized clinical trials
Hanyu Wang et al.
MEDICINE (2020)
Rapid fluorescence in situ hybridisation optimises induction therapy for acute myeloid leukaemia
Nya D. Nelson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Eun-Ji Choi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H. Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period
Gunnar Juliusson et al.
BLOOD (2019)
Venetoclax Combined with Cladribine plus Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Tapan M. Kadia et al.
BLOOD (2019)
Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Shannon R. McCurdy et al.
BLOOD (2019)
Validation of the Revised AML-Composite Model for the Prediction of Prognosis in Older Patients Receiving Intensive Induction Therapy
Corentin Orvain et al.
BLOOD (2019)
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
Richard F. Schlenk et al.
BLOOD (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML
Iman Aboudalle et al.
BLOOD (2019)
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Jorge E. Cortes et al.
LEUKEMIA (2019)
Geriatric assessment with management intervention in older adults with cancer: a randomized pilot study
Allison Magnuson et al.
SUPPORTIVE CARE IN CANCER (2018)
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS
Michael R. Savona et al.
CLINICAL CANCER RESEARCH (2018)
Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older
Victoria V. Prassek et al.
HAEMATOLOGICA (2018)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia
Prajwal Boddu et al.
LEUKEMIA & LYMPHOMA (2018)
Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older
Victoria V. Prassek et al.
HAEMATOLOGICA (2018)
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial
Tapan M. Kadia et al.
LANCET HAEMATOLOGY (2018)
Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)
Keith W. Pratz et al.
BLOOD (2018)
Limited FISH Testing for MDS-Defining Cytogenetic Abnormalities Rapidly Identifies Patients with Newly Diagnosed AML Eligible for CPX-351
Christine M. McMahon et al.
BLOOD (2018)
Augmentation of the Acute Myeloid Leukemia-Composite Model (AML-CM) with Performance Status and Secondary Leukemia
Sarah Elsayed et al.
BLOOD (2018)
Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
Hui Liu et al.
CLINICAL DRUG INVESTIGATION (2017)
A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia
A. K. Burnett et al.
LEUKEMIA (2017)
Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience
Mael Heiblig et al.
LEUKEMIA & LYMPHOMA (2017)
Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study
Giuseppe Visani et al.
LEUKEMIA RESEARCH (2017)
Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature
Kelly J. Norsworthy et al.
LEUKEMIA RESEARCH (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Abridged geriatric assessment is a better predictor of overall survival than the Karnofsky Performance Scale and Physical Performance Test in elderly patients with cancer
Marwan Ghosn et al.
JOURNAL OF GERIATRIC ONCOLOGY (2017)
Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality
Mohamed L. Sorror et al.
JAMA ONCOLOGY (2017)
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens
John F. Seymour et al.
BMC CANCER (2017)
Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy
Sang-Bo Oh et al.
ANNALS OF HEMATOLOGY (2017)
Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial
Agnieszka Pluta et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia
Alan K. Burnett et al.
BLOOD (2016)
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups
Marlise R. Luskin et al.
BLOOD (2016)
TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes
Tapan M. Kadia et al.
CANCER (2016)
Assessment of Minimal Residual Disease in Standard-Risk AML
A. Ivey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients 60 years old
Neha Gupta et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up
Federico Mosna et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States
Bruno C. Medeiros et al.
ANNALS OF HEMATOLOGY (2015)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
Alan K. Burnett et al.
BLOOD (2015)
Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale
S. Bonanad et al.
JOURNAL OF GERIATRIC ONCOLOGY (2015)
Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy
Zhentang Lao et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015)
Disparity in the Overall Survival Improvement over Time and the Effect Time-to-Treatment on the Outcome of Acute Promyelocytic Leukemia: A US National Cancer Data Base Study from 1998-2011
Aref Al-Kali et al.
BLOOD (2015)
Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: An analysis from a regional healthcare network
Pierre Bories et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification
Meir Wetzler et al.
HAEMATOLOGICA (2014)
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
Robert K. Hills et al.
LANCET ONCOLOGY (2014)
Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients
G. Visani et al.
LEUKEMIA (2014)
The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML)
Kathleen Elliot et al.
LEUKEMIA RESEARCH (2014)
Standard intensive chemotherapy is less effective and far more toxic than attenuated induction and post-induction regimen in elderly patients with acute myeloid leukemia
Bin-Tao Huang et al.
MEDICAL ONCOLOGY (2014)
The impact of abn(17p) and monosomy-5/del(5q) on the prognostic value of the monosomal karyotype in acute myeloid leukemia
Dimitri A. Breems et al.
BLOOD (2013)
Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia
Heidi D. Klepin et al.
BLOOD (2013)
Effect of NPM1 and FLT3 Mutations on the Outcomes of Elderly Patients With Acute Myeloid Leukemia Receiving Standard Chemotherapy
Naval Daver et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
When Azanucleoside Treatment Can Be Curative: Nonintensive Bridging Strategy Before Allografting in Older Patients With Myelodysplastic Syndrome/Acute Myeloid Leukemia
Michael Luebbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients
Lieke H. van der Helm et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making
F. Ferrara et al.
LEUKEMIA (2013)
Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts
L. H. van der Helm et al.
LEUKEMIA RESEARCH (2013)
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
Frank G. Rueckner et al.
BLOOD (2012)
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
Alfonso Quintas-Cardama et al.
BLOOD (2012)
Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia
Krzysztof Mrozek et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study
Jerzy Holowiecki et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Most 70-to 79-year-old patients with acute myeloid leukemia do benefit from intensive treatment
Gunnar Juliusson
BLOOD (2011)
A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia
Je-Hwan Lee et al.
BLOOD (2011)
Older Patients With Acute Myeloid Leukemia Benefit From Intensive Chemotherapy: An Update From the Swedish Acute Leukemia Registry
Gunnar Juliusson
Clinical Lymphoma Myeloma & Leukemia (2011)
Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum
Dimitri A. Breems et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cytarabine Dose for Acute Myeloid Leukemia
Bob Löwenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
Hagop Kantarjian et al.
BLOOD (2010)
Attempts to Optimize Induction and Consolidation Treatment in Acute Myeloid Leukemia: Results of the MRC AML12 Trial
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes
Utz Krug et al.
LANCET (2010)
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients
Mikkael A. Sekeres et al.
BLOOD (2009)
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial
Alan K. Burnett et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Superior Outcome With Hypomethylating Therapy in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome and Chromosome 5 and 7 Abnormalities
Farhad Ravandi et al.
CANCER (2009)
Medication Problems in Older, Newly Diagnosed Cancer Patients in Canada: How Common are They? A Prospective Pilot Study
Maribie T. E. Puts et al.
DRUGS & AGING (2009)
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Hugo F. Fernandez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Bob Lowenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Monosomal karyotype in acute myeloid leukemia:: A better indicator of poor prognosis than a complex karyotype
Dimitri A. Breems et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia
Rachid Baz et al.
CANCER (2007)
Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia
Anne Etienne et al.
CANCER (2007)
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
Alan K. Burnett et al.
CANCER (2007)
Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival
G Juliusson et al.
LEUKEMIA (2006)
Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies
KA Wouters et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
ML Sorror et al.
BLOOD (2005)
Trends in the treatment of acute myeloid leukaemia in the elderly
K Lang et al.
DRUGS & AGING (2005)
A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group
JM Rowe et al.
BLOOD (2004)
Randomized comparison of double induction and timed-sequential induction to a 3+7 induction in adults with AML:: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study
S Castaigne et al.
BLOOD (2004)
Congestive heart failure in patients treated with doxorubicin - A retrospective analysis of three trials
SM Swain et al.
CANCER (2003)
Timed sequential therapy of acute myelogenous leukemia in adults:: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide
J Bolaños-Meade et al.
LEUKEMIA RESEARCH (2003)
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
AH Goldstone et al.
BLOOD (2001)
分享论文
